Treatment of Frey’s syndrome using botulinum toxin type A

Treatment of Frey’s syndrome using botulinum toxin type A Of 49 patients to undergo parotidectomy during the past 6 years in our department, 18 (36.7%) subsequently noticed gustatory sweating. Of those 18, ten (20.4%) considered the sweating to be severe and very uncomfortable. Nine of the patients underwent Minor’s starch iodine test and Frey’s syndrome was confirmed. These patients were treated with an intracutaneous injection of 2.5 IU of botulinum toxin A (Botox, Allergan, USA) into the affected skin area. It was necessary to reinject the medicine into a small temporal hair-covered area in one patient, in whom Minor’s test did not appear clearly positive. The patients were subsequently evaluated with Minor’s test at 1 week, and then at 2, 6, 12 and 14 months, and were shown to be free of symptoms without any side effects. This preliminary report confirms that an intracutaneous injection of BT is an effective and safe treatment option for Frey’s syndrome. Further follow-up of the patients will be required to evaluate the duration of the therapeutic effect. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Plastic Surgery Springer Journals

Treatment of Frey’s syndrome using botulinum toxin type A

Loading next page...
 
/lp/springer_journal/treatment-of-frey-s-syndrome-using-botulinum-toxin-type-a-B8u9XphuvY
Publisher
Springer-Verlag
Copyright
Copyright © 2001 by Springer-Verlag
Subject
Medicine & Public Health; Plastic Surgery
ISSN
0930-343X
eISSN
1435-0130
D.O.I.
10.1007/s002380100297
Publisher site
See Article on Publisher Site

Abstract

Of 49 patients to undergo parotidectomy during the past 6 years in our department, 18 (36.7%) subsequently noticed gustatory sweating. Of those 18, ten (20.4%) considered the sweating to be severe and very uncomfortable. Nine of the patients underwent Minor’s starch iodine test and Frey’s syndrome was confirmed. These patients were treated with an intracutaneous injection of 2.5 IU of botulinum toxin A (Botox, Allergan, USA) into the affected skin area. It was necessary to reinject the medicine into a small temporal hair-covered area in one patient, in whom Minor’s test did not appear clearly positive. The patients were subsequently evaluated with Minor’s test at 1 week, and then at 2, 6, 12 and 14 months, and were shown to be free of symptoms without any side effects. This preliminary report confirms that an intracutaneous injection of BT is an effective and safe treatment option for Frey’s syndrome. Further follow-up of the patients will be required to evaluate the duration of the therapeutic effect.

Journal

European Journal of Plastic SurgerySpringer Journals

Published: Oct 23, 2001

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off